Clinical characteristics, healthcare resource use, and survival outcomes among patients with advanced NSCLC tested for KRAS mutations in France, the United Kingdom, and Switzerland
Patients with advanced NSCLC, regardless of KRAS mutation status, experience a substantial disease burden, frequent hospitalizations, and poor clinical outcomes. These findings highlight the urgent need for more effective treatment options for advanced NSCLC, including therapies tailored to KRAS-mutated disease.
Authors
- Andromachi Giannopoulou
- Sacha I. Rothschild (ORCID: https://orcid.org/0000-0003-1304-9340)
- Colin R. Lindsay (ORCID: https://orcid.org/0000-0001-8167-5461)
- Ihtisham Sultan (ORCID: https://orcid.org/0000-0002-9191-2501)
- Isabelle Borget (ORCID: https://orcid.org/0000-0002-5352-3521)
- Björn Stollenwerk (ORCID: https://orcid.org/0000-0002-3189-409X)
- Marie Wislez (ORCID: https://orcid.org/0000-0001-7518-7859)
- Joseph Milce
- Miklos Pless
- B Vincent
Institutions
- Oracle (United States) (US)
- Inserm (FR)
- Cerner (United States) (US)
- Université Paris Cité (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- University Hospital of Basel (CH)
- National Cancer Center (US)
- Centre de Recherche des Cordeliers (FR)
- La Ligue Contre le Cancer (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Kantonsspital Winterthur (CH)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- Kantonsspital Baden (CH)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- The Christie NHS Foundation Trust (GB)
- Amgen (Switzerland) (CH)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-07-21
- DOI
- https://doi.org/10.1080/13696998.2025.2535225
- Citations
- 1
- Primary Topic
- Genetic factors in colorectal cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.47